Affordable Access

Access to efavirenz and amprenavir.

Authors
  • Gilden, D
Type
Published Article
Journal
GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies
Publication Date
Oct 01, 1998
Volume
12
Issue
10
Pages
12–12
Identifiers
PMID: 11365902
Source
Medline
License
Unknown

Abstract

DuPont's new nonnucleoside analog, efavirenz (Sustiva), is embroiled in a controversy related to the high costs of the drug. DuPont has offered a 5 percent discount off of the current ADAP price, but several large ADAP programs are not including efavirenz yet. The company has committed to providing the drug free of charge to financially-needy patients, but only as a last resort. Recently, a new protease inhibitor called amprenavir (Agenerase) has been introduced by Glaxo Wellcome. Amprenavir is available from an expanded access program for patients who have failed one protease inhibitor and who fit into one of three treatment protocols. Problems with ingesting the drug are reviewed. Glaxo expects FDA approval for amprenavir in the near future.

Report this publication

Statistics

Seen <100 times